Leif G. Hanitsch

TL;DR: Evidence is provided that 29.5% of patients with CFS had elevated antibodies against one or more M acetylcholine and β adrenergic receptors which are potential biomarkers for response to B-cell depleting therapy and the association of autoantibodies with immune markers suggests that they activate B and T cells expressingβ adrenergic and M acetelcholine receptors.

TL;DR: The association of BALF cytokines with lung fibrosis and its progress suggests that cytokines contribute to the pathogenesis of ILD and hence could be regarded as potential therapeutic targets.

TL;DR: In this article, the authors show that in severe SARS-CoV-2, natural killer (NK) cells show remarkable defects in virus control, cytokine production and cell-mediated cytotoxicity despite high expression of cytotoxic effector molecules.

TL;DR: Identification of excessive IFN‐&ggr; production by blood and lymph node–derived T cells of patients with CVID with immune dysregulation will offer new therapeutic avenues for this subgroup.

TL;DR: Evidence is given for a deficient EBV-specific B- and T-cell memory response in CFS patients and an impaired ability to control early steps of EBV reactivation is suggested, suggesting the diminished EBV response might be suitable to develop diagnostic marker in C FS.